Literature DB >> 22993362

High levels of HMGB1 in plasma may be due to ex vivo cell necrosis.

Piotr Nowak1, Jessica Nystrom, Marius Troseid.   

Abstract

BACKGROUND: High mobility group box 1 protein (HMGB1) is considered an important biological marker during inflammation and malignancies. Here, we evaluated sample handling and effects of ex vivo necrosis on HMGB1 levels.
MATERIALS AND METHODS: Plasma samples were obtained from healthy volunteers (n=14) simulating the standard laboratory conditions, overnight incubations and harsh treatment. HMGB1 levels were evaluated by ELISA or western blot. Additionally, levels of hemoglobin, hemolysis index and lactate dehydrogenase were measured.
RESULTS: Plasma levels of HMGB1 were 9-fold increased in samples stored overnight at room temperature, as compared to those processed directly. The rapid centrifugation prevented the increase of HMGB1 in stored samples. Hemoglobin, hemolysis index and lactate dehydrogenase concentrations showed significant correlations with HMGB1 levels.
CONCLUSION: Handling of blood samples is important for the accurate estimation of systemic HMGB1. We propose that all samples with high HMGB1 concentrations should be evaluated for markers of ex vivo necrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993362

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  A microengineered model of RBC transfusion-induced pulmonary vascular injury.

Authors:  Jeongyun Seo; David Conegliano; Megan Farrell; Minseon Cho; Xueting Ding; Thomas Seykora; Danielle Qing; Nilam S Mangalmurti; Dongeun Huh
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

2.  Time-dependent expression of high-mobility group box-1 and toll-like receptors proteins as potential determinants of skin wound age in rats: Forensic implication.

Authors:  Yasmina M Abd-Elhakim; Bothina H F Omran; Shimaa A Ezzeldein; Amany I Ahmed; Nabela I El-Sharkawy; Amany Abdel-Rahman Mohamed
Journal:  Int J Legal Med       Date:  2022-02-07       Impact factor: 2.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.